Articles tagged "Antibodies"

2020 American Transplant Congress
The Clinical Usefulness of Preformed C1q-Binding Donor-Specific Antibodies in Kidney Transplantation
S. Lee, E. Ko, B. Chung, C. Yang
Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of
*Purpose: The anti-human leukocyte antigen (HLA) antibodies are well known for risk factor of rejection or allograft loss. Additionally, de novo complement component 1q-binding donor-specific…
2020 American Transplant Congress
Risk Stratification in Antibody Incompatible Kidney Transplantation: Can Aggressive Rejection be Avoided?
S. Punjala¹, M. Ibrahim¹, N. Vallant¹, N. Kessaris¹, O. Shaw², N. Mamode¹
¹Department of Nephrology, Renal Transplant and Urology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom, ²Clinical Transplantation Laboratory, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom
*Purpose: Our experience in antibody incompatible kidney transplantation, and anecdotal reports, suggest that a specific form of rejection, which we term Early Aggressive Antibody Mediated…
2020 American Transplant Congress
Development and Impact of DSA after Lung Transplant
M. Henderson¹, G. Morris², C. Burt¹, A. Feist¹, J. Kozuch¹, E. Schonhoft³, G. Yung³, T. Floreth³, K. Afshar³, E. Golts⁴, M. Mariski¹
¹Pharmacy, University of California San Diego Health, San Diego, CA, ²Immunology, University of California San Diego Health, San Diego, CA, ³Pulmonology, University of California San Diego Health, San Diego, CA, ⁴Cardiothoracic Surgery, University of California San Diego Health, San Diego, CA
*Purpose: Antibody-mediated rejection (AMR) after lung transplant (LT) is a serious complication, potentially leading to graft failure despite advances in drug therapy. Diagnosis and treatment…
2020 American Transplant Congress
The Clinical Significance of C1q+ Antibodies in Pediatric Kidney Transplant Recipients
N. Hayde¹, S. Solomon², A. Colovai¹
¹Montefiore Medical Center, Bronx, NY, ²Westchester Medical Center, Valhalla, NY
*Purpose: To evaluate the impact of denovo DSA (C1q+ vs C1q-) on graft outcomes in pediatric kidney transplant recipients.*Methods: Children transplanted between 2009 and 2016…
2020 American Transplant Congress
Daratumumab for Desensitization and Antibody Mediated Rejection Treatment in Highly-HLA Sensitized Patients
S. Jordan, R. Vescio, N. Ammerman, M. Toyoda, S. Ge, M. Chu, J. Hou, E. Huang, A. Peng, S. Sethi, R. Najjar, K. Lim, J. Kobashigawa, J. Patel, E. Kransdorf, A. Vo
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly-HLA sensitized (HS) patients have an immunologic barrier to transplantation. ABMR promotes graft loss and poor patient survival. Methods to reduce anti-HLA antibodies are…
2020 American Transplant Congress
Circulating Tissue Specific Exosomes Enable Noninvasive Diagnosis of Acute Cellular Rejection in Clinical Heart Transplantation
L. Korutla¹, R. Hu¹, C. Romano¹, M. Molina¹, C. Sciortino², C. Mullan³, R. McGargle², H. Kagawa², A. Kilic², A. Naji⁴, P. Vallabhajosyula³
¹Surgery, University of Pennsylvania, Philadelphia, PA, ²Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, ³Surgery, Yale University, New Haven, CT, ⁴University of Pennsylvania, Philadelphia, PA
*Purpose: There is a critical need for development of noninvasive biomarkers for allograft surveillance and diagnosis of rejection in heart transplant patients, as endomyocardial biopsy…
2020 American Transplant Congress
First Report of Successful CD38-Antagonist Daratumumab Augmented Carfilzomib-Based Treatment of Refractory Definite AMR of the Lung Allograft
M. N. Kildea¹, C. R. Ensor¹, J. Kim¹, L. Bogar¹, D. Colella¹, R. D. Davis¹, M. Marschner¹, A. Zeevi², N. Soe¹, C. Gries¹
¹AdventHealth, Orlando, FL, ²University of Pittsburgh, Pittsburgh, PA
*Purpose: Antibody-mediated rejection (AMR) after lung transplant (LT) is associated with early progressive chronic lung allograft dysfunction (CLAD) and death. Therapeutic regimens remain poorly evaluated.…
2020 American Transplant Congress
Development of DSA Class II is Associated with Immunosuppressive Monotherapy and Increased Risk for Graft Fibrosis, Chronic Rejection and Graft Loss
M. Sterneck¹, B. Sultani¹, A. Ozga², S. Weidemann³, J. Hermann⁴, E. Grabhorn⁵, U. Herden⁶, L. Fischer⁶
¹University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²Insitute of Medical Biometry, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Pathology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁴Pediatric Radiology, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁵Pediatric Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁶Transplant Surgery, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: Recent studies have suggested a negative impact of class 2 DSA on short term outcome of OLT recipients. The aim of this study was…
2020 American Transplant Congress
Comparison of Clinical Characteristics and Outcomes of Early Antibody-Mediated Rejection and Late Antibody-Mediated Rejection after Kidney Transplantation
G. Chen, Z. Wu, C. Wang, X. Liu, Q. Li, L. Chen
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
*Purpose: Antibody-mediated rejection(AMR) is a major risk factor for graft loss after kidney transplantation. Some AMR appeared within 6 months after kidney transplant, that we…
2020 American Transplant Congress
Comparison of 1-Year Incidence of De Novo Donor Specific Antibodies between Thymoglobulin and Alemtuzumab Induction in Kidney Transplantation
J. P. Knorr, C. Kallis, D. A. Portley, A. Jeyarajasingam, P. W. Lai, G. Bradauskaite, K. Khanmoradi
Transplant Nephrology, Einstein Medical Center, Philadelphia, PA
*Purpose: Development of de novo donor specific antibodies (dnDSA) after kidney transplantation (KTx) has been associated with acute and chronic antibody-mediated rejection, transplant glomerulopathy and…